Trials / Completed
CompletedNCT06124794
The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines
A Multicenter, Single Group, Open, Extension Study of Phase III Clinical Trial to Compare the Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Protox Inc. · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This clinical trial is an extended clinical trial for test subjects who participated in the phase 3 clinical trial of PT\_BTA\_P3\_21 (clinical trial plan number) and completed follow-up observation up to 16 weeks after administration of clinical trial drugs, and evaluates the effectiveness and safety of repeated administration of protoxin in those with moderate or severe brow wrinkles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PROTOXIN | Clostridium botulinum toxin type A |
Timeline
- Start date
- 2023-12-18
- Primary completion
- 2024-02-26
- Completion
- 2024-06-14
- First posted
- 2023-11-09
- Last updated
- 2024-06-21
Locations
3 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06124794. Inclusion in this directory is not an endorsement.